It is known that IL-6 is a mediator of tumorigenesis in several human malignancies [24,25,26], being overactive in many tumor types, including GC, and that the aberrant activation of the JAK/STAT pathway being dependant on IL-6 dictates development and resistance in GC. The gene discussed is IL6; the disease is gastric cancer.